Belite Bio, Inc Belite Bio, Inc

Belite Bio, Inc

BLTE

Classement en actions #3059
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the... Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
Prix de l'action
$148.24
Capitalisation boursière
$5.97B
Changement (1 jour)
3.82%
Changement (1 an)
69.01%
Pays
US
Échange Belite Bio, Inc (BLTE)

Catégorie

Healthcare
Historique du rendement du dividende pour Belite Bio, Inc (BLTE)
Le rendement du dividende (TTM) de Belite Bio, Inc (symbole boursier : BLTE) au 2023-12-31 est : 0.00%
Rendement moyen du dividende sur les 5 dernières années : 0.00%
Historique du rendement du dividende de Belite Bio, Inc (BLTE) de 2020 à 2026
Rendement du dividende à la fin de chaque année (TTM)
Année Rendement du dividende Changez
2026 (TTM) 0.00% 0.00%
2024 0.00% 0.00%
2023 0.00% 0.00%
2022 0.00% 0.00%
2021 0.00% 0.00%
2020 0.00% 0.00%
Rendements du dividende (TTM) pour des entreprises similaires ou concurrentes
Entreprise Rendement du dividende Pays
0.00%
US
0.00%
US
2.17%
AU
0.00%
CH
0.00%
NL